Try our Advanced Search for more refined results
September 18, 2018
United States Securities and Exchange Commission v. Clovis Oncology, Inc. et al
Case Number:
1:18-cv-02381
Court:
Nature of Suit:
Securities, Commodities, Exchange
Judge:
Companies
Government Agencies
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
September 18, 2018
Clovis To Pay $20M To End SEC Claims Over Cancer Drug
Biomedical firm Clovis Oncology Inc. and two of its executives will pay more than $20 million in penalties to resolve U.S. Securities and Exchange Commission claims that the company misled investors about the efficacy of its developmental lung cancer drug, the agency said Tuesday.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login